Resmed Inc. Stock
Resmed Inc. Stock
There is an upward development for Resmed Inc. compared to yesterday, with an increase of €4.00 (1.840%).
With 23 Buy predictions and not a single Sell prediction Resmed Inc. is an absolute favorite of our community.
With a target price of 259 € there is a slightly positive potential of 17.19% for Resmed Inc. compared to the current price of 221.0 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 1.840% | 5.590% | 2.839% | -3.240% | 5.995% | 12.092% | 21.429% |
| Thermo Fisher Scientific Inc. | -0.190% | 1.209% | 8.248% | -0.359% | 6.758% | -1.567% | 29.108% |
| Veeva Systems A | -0.580% | 5.825% | 5.101% | -6.041% | 4.360% | 33.429% | -13.858% |
| QuidelOrtho Corp. | -1.380% | 11.628% | 17.073% | -35.714% | 15.200% | -64.224% | -82.754% |
Comments
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
